Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring

References

• Diabetes Control and Complications Trial (DCCT) Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 2003 329 977 986
   Google Scholar
• Ohkubo Y Kishikawa H Araki E Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus Diabetes Res Clin Pract 1995 28 103 117 7587918
   PubMed Web of Science ®Google Scholar
• Hirsch IB Insulin analogues N Engl J Med 2005 352 174 183 15647580
   PubMed Web of Science ®Google Scholar
• Lepore M Pampanelli S Fanelli C Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro Diabetes 2000 49 2142 2148 11118018
   PubMed Web of Science ®Google Scholar
• Plank J Bodenlenz M Sinner F A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir Diabetes Care 2005 28 1107 1112 15855574
   PubMed Web of Science ®Google Scholar
• Heinemann L Linkeschova R Rave K Hompesch B Sedlak M Heise T Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo Diabetes Care 2000 23 644 649 10834424
   PubMed Web of Science ®Google Scholar
• Fanelli GC Pampanelli S Porcellati F Rossetti P Brunetti P Bolli GB Administration of neutral protamine Hagedorn insulin at bedtime versus dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial Ann Intern Med 2002 136 504 514 11926785
   PubMed Web of Science ®Google Scholar
• Jehle PM Micheler C Jehle DR Breitig D Boehm BO Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens Lancet 1999 354 1604 1607 10560676
   PubMed Web of Science ®Google Scholar
• Kølendorf K Bojsen J Deckert T Clinical factors influencing the absorption of 125I-NPH insulin in diabetic patients Horm Metab Res 1983 15 274 278 6409773
   PubMed Web of Science ®Google Scholar
• Wang F Carabino JM Vergara CM Insulin glargine: a systematic review of a long-acting insulin analogue Clin Ther 2003 25 1541 1577 12860485
   PubMed Web of Science ®Google Scholar
• Kurtzhals P Havelund S Jonassen I Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo Biochem J 1995 312 725 731 8554512
   PubMed Web of Science ®Google Scholar
• Havelund S Plum A Ribel U The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin Pharm Res 2004 21 1498 1504 15359587
   PubMed Web of Science ®Google Scholar
• Monnier L Colette C Owens DR Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2008 2 1094 1100 19885298
   PubMedGoogle Scholar
• Service FJ Molnar GD Rosevear JW Ackerman E Gatewood LC Taylor WF Mean amplitude of glycaemic excursions, a measure of diabetic instability Diabetes 1970 19 644 655 5469118
   PubMed Web of Science ®Google Scholar
• Molnar GD Taylor WF Ho MM Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability Diabetologia 1972 8 342 348 4641791
   PubMed Web of Science ®Google Scholar
• Hemkens LG Grouven U Bender R Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study Diabetologia 2009 52 1732 1744 19565214
   PubMed Web of Science ®Google Scholar
• Heise T Nosek L Ronn BB Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes Diabetes 2004 53 1614 1620 15161770
   PubMed Web of Science ®Google Scholar
• Klein O Lynge J Endahl L Damholt B Nosek L Heise T Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes Diabetes Obes Metab 2007 9 290 299 17391154
   PubMed Web of Science ®Google Scholar
• Porcellati F Rossetti P Busciantella NR Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study Diabetes Care 2007 30 2447 2452 17623819
   PubMed Web of Science ®Google Scholar
• Rosenstock J Davies M Home PD Larsen J Koenen C Schernthaner G A randomized, 52 week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes Diabetologia 2008 51 408 416 18204830
   PubMed Web of Science ®Google Scholar
• Heller S Koenen C Bode B Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial Clin Ther 2009 31 2086 2097 19922879
   PubMed Web of Science ®Google Scholar
• Pieber TR Treichel HC Hompesch B Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy Diabet Med 2007 24 635 642 17381500
   PubMed Web of Science ®Google Scholar
• Hollander P Cooper J Bregnhøj J Pedersen CB A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes Clin Ther 2008 30 1976 1987 19108786
   PubMed Web of Science ®Google Scholar
• Swinnen SG Dain MP Aronson R A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs Diabetes Care 2010 33 1176 1178 20200301
   PubMed Web of Science ®Google Scholar
• Raskin P Gylvin T Weng W Chaykin L Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes Diabetes Metab Res Rev 2009 25 542 548 19565569
   PubMed Web of Science ®Google Scholar
• Tone A Iseda I Higuchi C Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes Exp Clin Endocrinol Diabetes 2010 118 320 324 20072962
   PubMed Web of Science ®Google Scholar
• King AB Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study Diabetes Obes Metab 2009 11 69 71 19120433
   PubMed Web of Science ®Google Scholar
• King AB No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring J Diabetes Sci Technol 2010 4 151 154 20167179
   PubMedGoogle Scholar
• Wiesli P Krayenbuhl P Uthoff H Seifert B Schmid C Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: a prospective study in patients with type 2 diabetes Diabetologia 2009 52 1816 1819 19565212
   PubMed Web of Science ®Google Scholar
• Kawamori R Iwamoto Y Kadowaki T Iwasaki M Comparison of efficacy between insulin glargine and NPH human insulin in type 1 diabetes patients undergoing intensive insulin treatment – phase II/III clinical studies in Japan [in Japanese] Rinsho Iyaku 2003 19 423 440
   Google Scholar
• Kobayashi M Iwamoto Y Kaku K Kawamori R Tajima N 48-week randomized multicenter open-label parallel group phase 3 trial to compare insulin detemir and NPH insulin efficacy and safety in subjects with insulin requiring diabetes mellitus in a basal-bolus regimen [in Japanese] J Japan Diab Soc 2007 50 649 663
   Google Scholar